Agios Pharmaceuticals

Agios Highlights RISE UP Phase 3 Results at EHA 2026

CAMBRIDGE, Mass., June 13, 2026 Agios Pharmaceuticals, Inc. announced detailed results from the 52-week double-blind portion of the global...

By cGxPwire Editor
June 15, 2026

Bio-Pharma

UCB and Biogen Report Positive Phase 3 Lupus Results for Dapirolizumab Pegol in The Lancet

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 1, 2026 UCB and Biogen announced the publication of full Phase 3 PHOENYCS...

By cGxPwire Editor
June 2, 2026

Bio-Pharma

Agios Expands Rare Hematology Portfolio with Global Cevidoplenib Licensing Deal

CAMBRIDGE, Mass., June 1, 2026 Agios Pharmaceuticals has entered an exclusive global licensing agreement with South Korea-based Oscotec to...

By cGxPwire Editor
June 2, 2026

Pharma

Agios Secures EU Approval for PYRUKYND in Thalassemia

Cambridge, Massachusetts, USA, May 22, 2026 Agios Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorization...

By cGxPwire Editor
May 26, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Agios Pharmaceuticals

Agios Highlights RISE UP Phase 3 Results at EHA 2026

UCB and Biogen Report Positive Phase 3 Lupus Results for Dapirolizumab Pegol in The Lancet

Agios Expands Rare Hematology Portfolio with Global Cevidoplenib Licensing Deal

Agios Secures EU Approval for PYRUKYND in Thalassemia